These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37078252)

  • 21. BCL-xL Targeting to Induce Apoptosis and to Eliminate Chemotherapy-Induced Senescent Tumor Cells: From Navitoclax to Platelet-Sparing BCL-xL PROTACs.
    Skwarska A; Konopleva M
    Cancer Res; 2023 Nov; 83(21):3501-3503. PubMed ID: 37824434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of IAP-recruiting BCL-X
    Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic Action of MCL-1 Inhibitor with BCL-2/BCL-XL or MAPK Pathway Inhibitors Enhances Acute Myeloid Leukemia Cell Apoptosis and Differentiation.
    Opydo M; Mlyczyńska A; Mlyczyńska E; Rak A; Kolaczkowska E
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of a Novel BCL-X
    Pal P; Thummuri D; Lv D; Liu X; Zhang P; Hu W; Poddar SK; Hua N; Khan S; Yuan Y; Zhang X; Zhou D; Zheng G
    J Med Chem; 2021 Oct; 64(19):14230-14246. PubMed ID: 34533954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors.
    Zhu Y; Tchkonia T; Fuhrmann-Stroissnigg H; Dai HM; Ling YY; Stout MB; Pirtskhalava T; Giorgadze N; Johnson KO; Giles CB; Wren JD; Niedernhofer LJ; Robbins PD; Kirkland JL
    Aging Cell; 2016 Jun; 15(3):428-35. PubMed ID: 26711051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of a G-quadruplex-stabilizing small molecule that synergizes with Navitoclax to induce cytotoxicity in acute myeloid leukemia cells.
    Montoya JJ; Turnidge MA; Wai DH; Patel AR; Lee DW; Gokhale V; Hurley LH; Arceci RJ; Wetmore C; Azorsa DO
    BMC Cancer; 2019 Dec; 19(1):1251. PubMed ID: 31881855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural Insights into PROTAC-Mediated Degradation of Bcl-xL.
    Chung CW; Dai H; Fernandez E; Tinworth CP; Churcher I; Cryan J; Denyer J; Harling JD; Konopacka A; Queisser MA; Tame CJ; Watt G; Jiang F; Qian D; Benowitz AB
    ACS Chem Biol; 2020 Sep; 15(9):2316-2323. PubMed ID: 32697072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.
    Bogenberger JM; Kornblau SM; Pierceall WE; Lena R; Chow D; Shi CX; Mantei J; Ahmann G; Gonzales IM; Choudhary A; Valdez R; Camoriano J; Fauble V; Tiedemann RE; Qiu YH; Coombes KR; Cardone M; Braggio E; Yin H; Azorsa DO; Mesa RA; Stewart AK; Tibes R
    Leukemia; 2014 Aug; 28(8):1657-65. PubMed ID: 24451410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells.
    Gayle SS; Sahni JM; Webb BM; Weber-Bonk KL; Shively MS; Spina R; Bar EE; Summers MK; Keri RA
    J Biol Chem; 2019 Jan; 294(3):875-886. PubMed ID: 30482844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
    Moujalled DM; Pomilio G; Ghiurau C; Ivey A; Salmon J; Rijal S; Macraild S; Zhang L; Teh TC; Tiong IS; Lan P; Chanrion M; Claperon A; Rocchetti F; Zichi A; Kraus-Berthier L; Wang Y; Halilovic E; Morris E; Colland F; Segal D; Huang D; Roberts AW; Maragno AL; Lessene G; Geneste O; Wei AH
    Leukemia; 2019 Apr; 33(4):905-917. PubMed ID: 30214012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak.
    Kremer KN; Peterson KL; Schneider PA; Meng XW; Dai H; Hess AD; Smith BD; Rodriguez-Ramirez C; Karp JE; Kaufmann SH; Hedin KE
    J Biol Chem; 2013 Aug; 288(32):22899-914. PubMed ID: 23798675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins Bcl-2/Bcl-xl in HL-60 cells.
    Wang J; Yang D; Luo Q; Qiu M; Zhang L; Li B; Chen H; Yi H; Yan X; Li S; Sun J
    Int J Oncol; 2017 Aug; 51(2):563-572. PubMed ID: 28586007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.
    Shi J; Zhou Y; Huang HC; Mitchison TJ
    Cancer Res; 2011 Jul; 71(13):4518-26. PubMed ID: 21546570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
    Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
    Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of Bcl-xL overcomes polyploidy resistance and leads to apoptotic cell death in acute myeloid leukemia cells.
    Zhou W; Xu J; Gelston E; Wu X; Zou Z; Wang B; Zeng Y; Wang H; Liu A; Xu L; Liu Q
    Oncotarget; 2015 Aug; 6(25):21557-71. PubMed ID: 26188358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis.
    Jaiswal A; Jaiswal A; Williamson EA; Gelfond J; Zheng G; Zhou D; Hromas R
    Cancer Chemother Pharmacol; 2023 Jan; 91(1):89-95. PubMed ID: 36346454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
    Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Curcumin Combined with Thalidomide Reduces Expression of
    Mohammadi Kian M; Salemi M; Bahadoran M; Haghi A; Dashti N; Mohammadi S; Rostami S; Chahardouli B; Babakhani D; Nikbakht M
    Drug Des Devel Ther; 2020; 14():185-194. PubMed ID: 32021103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells.
    Wang Q; Wan J; Zhang W; Hao S
    Leuk Lymphoma; 2019 Sep; 60(9):2170-2180. PubMed ID: 30626241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The identification of BCL-XL and MCL-1 as key anti-apoptotic proteins in medulloblastoma that mediate distinct roles in chemotherapy resistance.
    Fitzgerald MC; O'Halloran PJ; Kerrane SA; Ní Chonghaile T; Connolly NMC; Murphy BM
    Cell Death Dis; 2023 Oct; 14(10):705. PubMed ID: 37898609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.